Literature DB >> 2208084

Potential use of D-glucaric acid derivatives in cancer prevention.

Z Walaszek1.   

Abstract

There is now growing evidence from animal models for the possible control of different stages of the carcinogenic process by the beta-glucuronidase inhibitor D-glucaro-1,4-lactone and its precursors such as D-glucaric acid salts, D-glucarates. D-Glucaric acid is a natural, non-toxic compound produced in small amounts by mammals, including humans. It was recently found in some vegetables and fruits. D-Glucaro-1,4-lactone and D-glucarate exhibit potent antiproliferative properties in vivo. Some human subpopulations could have reduced risk of cancer development by ingesting food rich in D-glucaric acid or self-medication with D-glucarates alone or in combination with other chemopreventive agents.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2208084     DOI: 10.1016/0304-3835(90)90083-a

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  14 in total

Review 1.  The role of beta-glucuronidase in drug disposition and drug targeting in humans.

Authors:  B Sperker; J T Backman; H K Kroemer
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

2.  Evaluation of the thiazole Schiff bases as β-glucuronidase inhibitors and their in silico studies.

Authors:  Khalid Mohammed Khan; Aneela Karim; Sumayya Saied; Nida Ambreen; Xayale Rustamova; Shagufta Naureen; Sajid Mansoor; Muhammad Ali; Shahnaz Perveen; M Iqbal Choudhary; Guillermo Antonio Morales
Journal:  Mol Divers       Date:  2014-02-18       Impact factor: 2.943

3.  Dietary D-glucarate effects on the biomarkers of inflammation during early post-initiation stages of benzo[a]pyrene-induced lung tumorigenesis in A/J mice.

Authors:  Robert Zoltaszek; Piotr Kowalczyk; Magdalena C Kowalczyk; Margaret Hanausek; Zofia M Kilianska; Thomas J Slaga; Zbigniew Walaszek
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

4.  In vitro study of the antioxidative properties of the glucose derivatives against oxidation of plasma components.

Authors:  Joanna Kolodziejczyk; Joanna Saluk-Juszczak; Barbara Wachowicz
Journal:  J Physiol Biochem       Date:  2010-11-19       Impact factor: 4.158

5.  Serum beta-glucuronidase activity in response to fruit and vegetable supplementation: a controlled feeding study.

Authors:  Sonia S Maruti; Jyh-Lurn Chang; Jo Ann Prunty; Jeannette Bigler; Yvonne Schwarz; Shuying S Li; Lin Li; Irena B King; John D Potter; Johanna W Lampe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-07       Impact factor: 4.254

6.  Dietary and demographic correlates of serum beta-glucuronidase activity.

Authors:  Sonia S Maruti; Lin Li; Jyh-Lurn Chang; Joann Prunty; Yvonne Schwarz; Shuying S Li; Irena B King; John D Potter; Johanna W Lampe
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

7.  Cloning and characterization of uronate dehydrogenases from two pseudomonads and Agrobacterium tumefaciens strain C58.

Authors:  Sang-Hwal Yoon; Tae Seok Moon; Pooya Iranpour; Amanda M Lanza; Kristala Jones Prather
Journal:  J Bacteriol       Date:  2008-12-05       Impact factor: 3.490

8.  Targeted gene disruption coupled with metabolic screen approach to uncover the LEAFY COTYLEDON1-LIKE4 (L1L4) function in tomato fruit metabolism.

Authors:  Custódia Gago; Victoria Drosou; Konstantinos Paschalidis; Adriana Guerreiro; Graça Miguel; Dulce Antunes; Zoe Hilioti
Journal:  Plant Cell Rep       Date:  2017-04-08       Impact factor: 4.570

9.  Development of a gas chromatography-mass spectrometry method for the quantification of glucaric Acid derivatives in beverage substrates.

Authors:  Ana Paula Craig; Christine C Fields; John V Simpson
Journal:  Int J Anal Chem       Date:  2014-06-15       Impact factor: 1.885

10.  Rikkunshito Ameliorates Cancer Cachexia Partly through Elevation of Glucarate in Plasma.

Authors:  Katsuya Ohbuchi; Shin Nishiumi; Naoki Fujitsuka; Tomohisa Hattori; Masahiro Yamamoto; Akio Inui; Takeshi Azuma; Masaru Yoshida
Journal:  Evid Based Complement Alternat Med       Date:  2015-09-15       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.